```html

Klebsiella pneumoniae Carbapenem‑Resistant Infection

Overview

Klebsiella pneumoniae is a gram‑negative rod‑shaped bacterium that normally lives in the intestines and throat of healthy people. When it acquires resistance to carbapenems—our most powerful class of antibiotics—it becomes a “carbapenem‑resistant Klebsiella pneumoniae” (CRKP). This resistance makes infections difficult to treat and is a major public‑health concern worldwide.

Who it affects: CRKP most often spreads in hospitals and long‑term care facilities, so patients with recent hospitalization, invasive devices (catheters, ventilators), or prolonged antibiotic use are at highest risk. Community‑acquired cases have been reported, especially in regions with high antimicrobial resistance, but they remain far less common than health‑care‑associated cases.

Prevalence: According to the U.S. Centers for Disease Control and Prevention (CDC), around 13,000 CRKP infections were reported in U.S. acute‑care hospitals in 2022, with a mortality rate of roughly 30–50 % for bloodstream infections [CDC 2023]. In Europe, the European Centre for Disease Prevention and Control (ECDC) estimates that carbapenem‑resistant Enterobacteriaceae, including CRKP, cause >30,000 infections per year [ECDC 2022]. The World Health Organization (WHO) lists carbapenem‑resistant K. pneumoniae as a “critical” priority pathogen for new drug development [WHO 2023].

Symptoms

The clinical picture depends on the infection site. Below is a comprehensive list of possible manifestations.

Respiratory tract

• Pneumonia: fever, chills, productive cough with purulent sputum, shortness of breath, pleuritic chest pain, and sometimes hemoptysis.
• Ventilator‑associated pneumonia (VAP): new or worsening infiltrates on chest X‑ray plus fever, increased ventilator settings, and purulent tracheal secretions.

Urinary tract

• Dysuria, urgency, frequency, suprapubic pain.
• Flank pain or kidney tenderness if the infection ascends (pyelonephritis).
• Cloudy, foul‑smelling urine; possible hematuria.

Bloodstream (bacteremia / sepsis)

• High fever, chills, rigors.
• Hypotension, tachycardia, altered mental status.
• Diffuse organ dysfunction (e.g., acute kidney injury, liver enzyme elevation).

Wound / surgical site

• Redness, warmth, swelling, purulent drainage.
• Increasing pain around the incision or traumatic wound.
• Fever and malaise if infection spreads.

Other possible presentations

• Endocarditis: new murmur, embolic phenomena, heart failure signs.
• Meningitis (rare): severe headache, neck stiffness, photophobia, altered consciousness.

Causes and Risk Factors

How resistance develops

Carbapenem resistance in K. pneumoniae is usually mediated by enzymes called carbapenemases (e.g., KPC, NDM, OXA‑48‑like). These enzymes break down carbapenems, rendering them ineffective. Resistance genes are often carried on plasmids—small, mobile DNA fragments—that can transfer between bacteria, spreading the trait quickly.

Key risk factors

• Recent hospitalization (especially >5 days) or admission to an intensive care unit.
• Use of invasive devices: central venous catheters, urinary catheters, endotracheal tubes, feeding tubes.
• Broad‑spectrum antibiotic exposure within the past 3 months, especially carbapenems, quinolones, or third‑generation cephalosporins.
• Immunocompromised state: chemotherapy, solid‑organ transplantation, HIV/AIDS with CD4 <200 cells/µL, or chronic corticosteroid use.
• Underlying chronic diseases: diabetes mellitus, chronic kidney disease, chronic lung disease.
• Living in long‑term care facilities or nursing homes.
• Previous colonization or infection with multidrug‑resistant organisms.

Diagnosis

Prompt and accurate identification is essential because treatment options are limited.

Clinical evaluation

• Detailed history of recent healthcare exposure, antibiotics, and device use.
• Physical examination focused on the suspected infection site.

Laboratory tests

• Culture and sensitivity: Blood, urine, sputum, wound swab, or cerebrospinal fluid samples are sent for bacterial culture. Automated systems (e.g., VITEK, MALDI‑TOF) identify K. pneumoniae and run susceptibility panels.
• Carbapenemase detection:
  • Phenotypic tests: Modified Hodge Test, Carba NP, or Carbapenem Inactivation Method.
  • Molecular PCR assays that detect genes such as blaKPC, blaNDM, blaOXA‑48.
• Imaging: Chest X‑ray or CT scan for pneumonia, abdominal CT for intra‑abdominal infection, ultrasound for complicated urinary infections.
• Serum markers: CBC (leukocytosis), CRP, procalcitonin (helpful to gauge severity of sepsis).

Screening for colonization

Rectal or perineal swabs performed on high‑risk patients help detect asymptomatic carriage, allowing infection‑control measures to be instituted before infection occurs [CDC 2023].

Treatment Options

Because CRKP is resistant to most standard antibiotics, therapy must be individualized based on susceptibility results, infection severity, and patient factors.

First‑line antimicrobial regimens (based on susceptibility)

• Polymyxins: Colistin (intravenous) or polymyxin B. Nephrotoxic; requires renal monitoring.
• Tigecycline: Useful for skin, soft‑tissue, and intra‑abdominal infections; limited serum concentrations—avoid as monotherapy for bloodstream infections.
• Fosfomycin: Intravenous formulation (fosfomycin disodium) can be combined with other agents; good urinary penetration.
• Newer β‑lactam/β‑lactamase inhibitor combos:
  • Cefiderocol (FDA‑approved 2020) – a siderophore cephalosporin active against many carbapenem‑resistant Enterobacteriaceae.
  • Meropenem‑vaborbactam (Vabomere) – effective for KPC‑producing isolates.
  • Imipenem‑relebactam – limited activity against KPC, not NDM/OXA‑48.

Combination therapy

Guidelines from the Infectious Diseases Society of America (IDSA) recommend using at least two active agents for serious CRKP infections to improve outcomes and reduce emergence of further resistance [IDSA 2023]. Typical combinations include:

• Colistin + tigecycline
• Meropenem‑vaborbactam + aztreonam (if the isolate is metallo‑β‑lactamase producer)
• Cefiderocol + fosfomycin

Adjunctive measures

• Source control: Remove or replace infected catheters, drain abscesses, debride necrotic tissue, or perform surgical intervention when indicated.
• Supportive care: Fluid resuscitation, vasopressors for septic shock, oxygen or mechanical ventilation for respiratory failure.
• Therapeutic drug monitoring (TDM): Especially for colistin and aminoglycosides to balance efficacy and toxicity.

Lifestyle & supportive actions

• Stay hydrated and follow nutrition recommendations to support immune function.
• Adhere strictly to prescribed antibiotic schedule—never skip doses.
• Maintain good hygiene (handwashing, wound care) to reduce secondary infections.

Living with Klebsiella pneumoniae Carbapenem‑Resistant Infection

Living with CRKP can be challenging, but proactive measures can improve quality of life and reduce recurrence.

Medication adherence

• Use a pill organizer or smartphone reminders.
• Discuss side‑effects with your provider; many agents (colistin, tigecycline) can cause nausea, kidney issues, or liver enzyme elevation.

Home care and infection control

• Hand hygiene: Wash hands with soap for at least 20 seconds before touching wounds, catheters, or food.
• Environmental cleaning: Disinfect high‑touch surfaces (doorknobs, bathroom fixtures) daily with EPA‑registered disinfectants effective against gram‑negative bacteria.
• Device management: If you have a urinary catheter or central line at home, follow sterile techniques for dressing changes and seek help immediately if the site becomes red, swollen, or drains pus.

Monitoring & follow‑up

• Schedule regular lab work (renal function, liver enzymes, complete blood count) as directed.
• Attend all outpatient infectious‑disease appointments; the provider may repeat cultures to confirm clearance.
• Report new fevers, chills, or worsening pain promptly.

Psychosocial support

• Join support groups for patients with multidrug‑resistant infections.
• Consider counseling if anxiety or depression develops—living with a “superbug” can be stressful.

Prevention

Most CRKP cases are healthcare‑associated, so prevention focuses on hospital and community measures.

In health‑care settings

• Hand hygiene compliance: WHO “Five Moments for Hand Hygiene” for all staff and visitors.
• Contact precautions: Gown and gloves for patients known or suspected to carry CRKP.
• Active surveillance cultures: Routine rectal swabs in high‑risk units (ICU, transplant wards).
• Antimicrobial stewardship: Limit unnecessary carbapenem use; de‑escalate therapy based on culture data.
• Environmental cleaning: Daily and terminal cleaning with agents effective against gram‑negative rods.

At home and in the community

• Practice proper handwashing, especially after using the bathroom and before preparing food.
• Avoid sharing personal items (towels, razors) with a person known to be colonized.
• Complete all prescribed antibiotics for any infection, even if you feel better.
• If you have a chronic wound or catheter, have a health‑care professional educate you on sterile handling.

Complications

Untreated or inadequately treated CRKP infections can lead to serious, sometimes fatal, complications.

• Septic shock: Profound hypotension requiring vasopressors; mortality up to 50 %.
• Organ failure: Acute kidney injury, acute respiratory distress syndrome (ARDS), hepatic dysfunction.
• Metastatic infections: Endocarditis, osteomyelitis, or meningitis originating from a primary site.
• Persistent colonization: Ongoing carriage can seed future infections and facilitate spread to others.
• Clostridioides difficile infection: Broad‑spectrum antibiotics disrupt gut flora, increasing CDI risk.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. “Antibiotic Resistance Threats in the United States, 2019–2023.” CDC, 2023.
• European Centre for Disease Prevention and Control. “Antimicrobial Resistance Surveillance in Europe 2022.” ECDC, 2022.
• World Health Organization. “Global Priority List of Antibiotic‑Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics.” WHO, 2023.
• Infectious Diseases Society of America. “Guidelines for the Treatment of Antimicrobial‑Resistant Gram‑Negative Bacterial Infections.” IDSA, 2023.
• Mayo Clinic. “Klebsiella pneumoniae infection.” Mayo Clinic, accessed May 2026.
• Cleveland Clinic. “Carbapenem‑Resistant Enterobacteriaceae (CRE).” Cleveland Clinic, 2024.

```